文献速递湿疹皮炎与荨麻疹

奥马珠单抗对难治性慢性特发性/自发性荨麻疹伴血管性水肿患者血管性水肿及生活质量的正向影响:基于有无血管性水肿的分析

Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2017-01-17

本研究分析奥马珠单抗对难治性慢性特发性/自发性荨麻疹(CIU/CSU)伴或不伴血管性水肿患者血管性水肿和生活质量的影响。患者每4周接受奥马珠单抗75、150或300 mg或安慰剂治疗12/24周。结果显示,基线有血管性水肿的患者中,奥马珠单抗300 mg组较安慰剂组在12和24周时血管性水肿每周发生率和每周发生天数均显著降低,DLQI评分改善超过最小临床重要差异阈值。

要点

  • 奥马珠单抗300 mg可显著降低伴血管性水肿的难治性CIU/CSU患者血管性水肿发生频率和天数。
  • 奥马珠单抗300 mg对生活质量的改善超过最小临床重要差异阈值。
  • 较低剂量奥马珠单抗与安慰剂比较结果不一致。

核心结论

  • 与安慰剂相比,奥马珠单抗300 mg治疗12-24周可显著减少血管性水肿发生率和每周发生天数,并伴随有临床意义的生活质量改善。

研究设计与样本

  • 患者每4周接受奥马珠单抗75、150或300 mg或安慰剂治疗12/24周,亚组基于随机化前7天基线血管性水肿的有无划分。

主要发现

  • 基线有血管性水肿且随机分配至奥马珠单抗300 mg的患者,在12和24周时血管性水肿每周平均发生率和每周平均发生天数较安慰剂组降低更明显。
  • 奥马珠单抗300 mg组较安慰剂组DLQI评分平均多降低3.3至4.5分,超过最小临床重要差异阈值。
  • 较低剂量奥马珠单抗与安慰剂比较结果不一致。

临床怎么用

  • 对于难治性CIU/CSU伴血管性水肿的患者,可考虑使用奥马珠单抗300 mg每4周一次以降低血管性水肿发生并改善生活质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Approximately 50% of patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) report hives and angioedema; some experience hives/angioedema only. OBJECTIVE: Assess omalizumab's effect on angioedema and quality of life (QoL) in subgroups with refractory CIU/CSU: those with and without angioedema. METHODS: Patients received omalizumab (75, 150 or 300 mg) or placebo every 4 weeks for 12/24 weeks. Angioedema and QoL were assessed [Urticaria Patient Daily Diary and Dermatology Quality of Life Index (DLQI)]. Subgroups were based on the presence/absence of baseline angioedema 7 days prior to randomization. RESULTS: Patients with baseline angioedema randomized to omalizumab 300 mg had a greater reduction in mean weekly incidence of angioedema and mean number of days/week with angioedema vs. placebo at 12 and 24 weeks. A 3.3- to 4.5-point greater mean reduction in DLQI score was achieved with omalizumab 300 mg treatment vs. placebo, above the minimal clinically important difference threshold. Results with lower doses vs. placebo were variable. CONCLUSION: Compared with placebo, omalizumab 300 mg treatment over 12-24 weeks resulted in marked reduction in incidence and number of days/week with angioedema accompanied by clinically relevant improvement in QoL.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Maurer M, Sofen H, Ortiz B, et al. Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema. J Eur Acad Dermatol Venereol. 2017. PMID: 27911016. doi:10.1111/jdv.14075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。